Off-Label Ruling Opens Window For Shift In FDA Regulation, PhRMA Says
Executive Summary
PhRMA would like FDA to focus on the quality of off-label communication rather than the intent; one attorney says the Caronia decision may result in reduced government settlements and another warns of reading the ruling too favorably for industry.